Danish drugmaker Novo Nordisk has partnered with Hims & Hers Health's to sell its popular weight loss drug through a bundled ...

Since launching its wildly popular weight-loss drug Wegovy in 2021, Novo Nordisk has raised its annual sales guidance several ...

Novo Holdings, the controlling shareholder of obesity drugmaker Novo Nordisk , nearly doubled annual income and investment ...

Reuters, the news and media division of Thomson Reuters, is the world’s largest multimedia news provider, reaching billions ...

Novo Nordisk has launched its hugely popular weight-loss drug Wegovy in Thailand, an executive of the Danish drugmaker's ...

The pecking order of the obesity drug market is shifting. Eli Lilly , the $815 billion maker of blockbuster weight-loss drugs ...

A judge denied compounders' request to keep making off-brand Wegovy and Ozempic after the FDA removed semaglutide from its shortage list.

Novo Nordisk (NVO) closed the latest trading day at $62.62, indicating a +0.87% change from the previous session's end. This move outpaced the S&P 500's daily gain of 0.06%. At the same time, the Dow ...

The decision came in response to a February lawsuit from a compounding industry group against the FDA's decision that there ...

By Sukriti Gupta and Medha Singh (Reuters) -European shares fell on Tuesday, dragged down by heavyweight Novo Nordisk, while ...

Since launching its wildly popular weight-loss drug Wegovy in 2021, Novo Nordisk has raised its annual sales guidance several ...